11 news items
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX
10 Jun 24
Study of ELI-002 7P in patients with mKRAS-driven solid tumors was well tolerated with T cell responses correlating with a reduction in tumor biomarkers
Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With mKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting
ELTX
24 May 24
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
15 May 24
the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR Annual Meeting
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
that are positive for minimal residual disease. ELI-002 7P is designed to stimulate an immune response against the seven KRAS mutations that drive 25
p2p9kgw8o5w7riy51 u9a5luylqvar3wwzmyn2a9fc3h
ELTX
24 Apr 24
that delivers immunotherapies to the lymph nodes to produce large cancer-fighting T-cell responses. The company is currently using this technology to test
tloh6aer dfi3qu
ELTX
11 Apr 24
is working to re-engineer the body's immune response to defeat cancer and infectious diseases with potent lymph node-targeted immunotherapies
r9nt51uakpvooh2cv1ui3pzsjr
ELTX
5 Apr 24
booster dose were observed to have durable mKRAS-specific T cell response with increased memory T cell phenotypePreclinical studies
cdluf3 yz
ELTX
5 Apr 24
The majority of patients who received a ELI-002 booster dose were observed to have durable mKRAS-specific T cell response with increased
602ud5g9zqt1aqnrtqd7qcv6l2pznz1uy4i3xg4854a2c4b7
ELTX
5 Apr 24
and hormonal therapies. Another treatment option is immunotherapy, which is designed to utilize the immune system to fight cancer. Immune responses
7awkqdp1md4vt6j1uvsisz m4
ELTX
5 Apr 24
and hormonal therapies. Another treatment option is immunotherapy, which is designed to utilize the immune system to fight cancer. Immune responses
- Prev
- 1
- Next